This site is intended for U.S. healthcare professionals.​​​​​​​

Report Adverse EventSearch

Menu

Close

Sign InLog Out Products & DiseasesCongressesPublicationsResourcesContact
You are now leaving PfizerPro You are about to view a medical resource regarding the use of tofacitinib in Juvenile Idiopathic Arthritis.  Before viewing this content, please note that the US Prescribing Information for Xeljanz was updated following FDA’s completed review of the ORAL Surveillance Study, an FDA-required postmarketing safety study. The final results of the ORAL Surveillance study have prompted important changes to the US prescribing information for tofacitinib.

ORAL surveillance was a large randomized active-controlled event-powered non-inferiority clinical trial to evaluate the safety of tofacitinib at two doses (5 mg twice daily and 10 mg twice daily) versus two tumor necrosis factor alpha inhibitors (TNF-alpha inhibitors) in subjects with Rheumatoid Arthritis who were 50 years of age or older and had at least one additional cardiovascular risk factor.  The co-primary endpoints of this study were adjudicated major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancers). Study results showed that the prespecified non-inferiority criteria were not met for these co-primary endpoints and the clinical trial could not demonstrate tofacitinib is non-inferior to (“not worse than”) TNF-alpha inhibitors.

Please refer to the US Prescribing Information.

By selecting “Continue to JIA Video” below, you acknowledge and certify that you are aware of the key findings from the ORAL Surveillance study.  Additional information is available on this medical portal.
Products & Diseases

This section contains educational resources and information relating to Pfizer-approved medicines and therapeutic areas of interest.

This section contains educational resources and information relating to Pfizer approved medicines and therapeutic areas of interest.

ProductsDisease State
For additional information on our medicines and vaccines, you can find more content on Pfizer Medical Information
Tab 2 Intro Section.....
Products:Disease State:ProductsDisease State
For additional information on our medicines and vaccines, you can find more content on Pfizer Medical Information.
Product:Disease State:
No Products & Diseases currently available

Check back soon to see if new Products & Diseases have been added, or try looking for another therapy area.

This site is only intended for healthcare professionals and is designed to provide relevant background and scientific findings concerning Pfizer products and areas of therapeutic interest. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Pfizer does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. If you are a member of the public wishing to access information on specific medicines, please visit Pfizer Medical Information.

This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.

Pfizer Account

To access further materials and resources and receive communication about medicines and vaccines promoted by Pfizer.

Account Sign In Register Sign Out

Pfizermedical.pfizerpro.com content may include hyperlinks to external websites. Links to external websites are provided as a resource to the viewer. These external websites are neither owned, endorsed, nor controlled by Pfizer Inc. Pfizer accepts no responsibility for the content or services of a linked site.  The terms of use and privacy policy of external sites may be different from our site. Any opinions, claims, or comments expressed on external sites should not be attributed to Pfizer.

© 2025 Pfizer Inc. All rights reserved.

 
These resources may include educational resources and information relating to Pfizer medicines and therapeutic areas of interest, congress materials and publications.

This content is intended for your personal, educational use only.  Please do not download or distribute further. No further reproduction or distribution is permitted without permission from copyright owner(s).

By selecting continue below, you acknowledge and certify that you are a US Healthcare Professional.

You are now leaving Pfizer Medical You are now leaving pfizermedical.pfizerpro.com. Links to external websites are provided as a resource to the viewer. These external websites are neither owned, endorsed, nor controlled by Pfizer Inc. 

Pfizer accepts no responsibility for the content or services of a linked site.  Any opinions, claims, or comments expressed on external sites should not be attributed to Pfizer.